Greka Anna 4

What Happened

• Anna Greka, a director of Ovid Therapeutics, received a derivative award (stock option) for 130,000 shares on June 15, 2026. The Form 4 reports the acquisition as an award (code A) with $0.00 cash paid at grant; total reported value on the filing is $0. This is an equity compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (filed within the standard 2-business-day window).
• Amount: 130,000 shares (derivative option award) at $0.00 reported price.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: The options will vest in 36 equal monthly installments beginning July 15, 2026, subject to continued service.
• Transaction type: Award/Grant (A); not an immediate exercise or sale.

Context

• This filing documents a grants-based compensation award. The option grant does not represent immediate ownership of shares until vesting and any required exercise; it’s a standard form of director compensation and does not by itself indicate buying or selling behavior.